Biofrontera

Biofrontera Operating Expenses

The Total Operating Expenses of Biofrontera (B8FK.DE) as of Nov 21, 2026 is 5.42 M EUR. In the previous year, Total Operating Expenses was 4.85 M EUR — a change of 11.65% (higher).

Operating Expenses

5.42 MEUR

YoY

11.65%

Last updated:

Total Operating Expenses of Biofrontera is 2025 5.42 M EUR. Total Operating Expenses of Biofrontera was 2024 4.85 M EUR. It decreases by 11.65% higher compared to the previous year.

The Biofrontera Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2018
17.39 M EUR
Jan 1, 2019
20.91 M EUR
Jan 1, 2020
13.94 M EUR
Jan 1, 2021
37.79 M EUR
Jan 1, 2022
13.03 M EUR
Jan 1, 2023
13.95 M EUR
Jan 1, 2024
4.85 M EUR
Jan 1, 2025
5.42 M EUR
The Biofrontera Operating Expenses history
YEAROperating ExpensesYoY
5.42 MEUR+11.65%
4.85 MEUR-65.23%
13.95 MEUR+7.04%
13.03 MEUR-65.51%
37.79 MEUR+171.11%
13.94 MEUR-33.34%
20.91 MEUR+20.25%
17.39 MEUR+137.50%
7.32 MEUR-2.29%
7.49 MEUR-16.40%
8.96 MEUR+17.04%
7.66 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

Total Operating Expenses of Biofrontera is 5.42 M EUR in 2025.

Total Operating Expenses of Biofrontera changed from 4.85 M EUR to 5.42 M EUR, representing a 11.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Biofrontera since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Biofrontera historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Biofrontera

All Key Metrics — Biofrontera